Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

Go back to Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Along Mobile Technologies, Inc. (NASDAQ: AGMB) Delayed: 9.26 +0.15 (1.65%)
Previous Close $9.11    52 Week High $0.01 
Open $9.15    52 Week Low $0.01 
Day High $9.44    P/E N/A 
Day Low $8.90    EPS $0.00 
Volume 84,322